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Colorectal cancer stem cells (CSCs) express Lgr5
and display extensive stem cell-like multipotency
and self-renewal and are thought to seed metastatic
disease. Here, we used a mouse model of colorectal
cancer (CRC) and human tumor xenografts to inves-
tigate the cell of origin of metastases. We found that
most disseminated CRC cells in circulation were
Lgr5 and formed distant metastases in which
Lgr5+ CSCs appeared. This plasticity occurred
independently of stemness-inducing microenviron-
mental factors and was indispensable for outgrowth,
but not establishment, of metastases. Together,
these findings show that most colorectal cancer me-
tastases are seeded by Lgr5 cells, which display
intrinsic capacity to become CSCs in a niche-inde-
pendent manner and can restore epithelial hierar-
chies in metastatic tumors.
INTRODUCTION
Epithelial tissues are hierarchically organized: a small pool of
replicative immortal and self-renewing stem cells (SCs) give
rise to a large population of more specialized cells that are
replicative mortal (Beck and Blanpain, 2013). During develop-
ment, SCs drive long-term growth, while during adult life they
sustain tissues by driving turnover of short-lived specialized
cells (Donati and Watt, 2015; Soteriou and Fuchs, 2018).
This hierarchical organization is proposed to be maintained
in tumors (Batlle and Clevers, 2017; Beck and Blanpain,Cell Stem Cell 26, 569–578
This is an open access article und2013; Nassar and Blanpain, 2016). Indeed, cell-sorting and
transplantation experiments showed that only a small pool
of cancer cells, often referred to as cancer SCs (CSCs),
have the ability to grow tumors in mice (Al-Hajj et al., 2003;
Bonnet and Dick, 1997; Ricci-Vitiani et al., 2007). More
recently, lineage-tracing experiments provided proof of the
existence of CSCs in unperturbed tumors, including glioblas-
toma (Chen et al., 2012), squamous skin tumors (Driessens
et al., 2012), colorectal cancer (CRC) (Cortina et al., 2017;
Schepers et al., 2012; Shimokawa et al., 2017) and breast
cancer (Zomer et al., 2013). In addition to the role in tumor
growth and homeostasis, CSCs are thought to be important
for metastasis. The essential role of CSCs in the metastatic
process is reinforced by studies showing that metastasizing
cells acquire SC properties, for example, through epithelial-
to-mesenchymal transition (Guo et al., 2012; Mani et al.,
2008; Ye et al., 2015). Indeed, selective depletion of CSCs
in primary tumors protects from the appearance of distant
metastases (de Sousa e Melo et al., 2017). The role of CSCs
in metastasis would be particularly crucial if the tumor cell hi-
erarchy is a rigid one-way route, from SCs to more specialized
cells (Meacham and Morrison, 2013). However, epithelial hier-
archical organization can be dynamic (Medema, 2013). For
example, in healthy tissues, upon damage or selective abla-
tion of the SC population, more specialized cells can acquire
SC traits (Ritsma et al., 2014; Tetteh et al., 2016; Tian et al.,
2011; van Es et al., 2012). This process of cellular plasticity
ensures repopulation of impaired SC niches and reestablish-
ment of tissue homeostasis. Whether cellular plasticity also
plays an important role in metastasis is unknown. In this
study, we dissect the different steps of the metastatic
cascade (cell migration, intravasation, metastatic seeding,
and outgrowth) and uncover the roles of CSCs, non-CSCs,
and cellular plasticity in metastasis., April 2, 2020 ª 2020 The Authors. Published by Elsevier Inc. 569
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Figure 1. Generation of a Colorectal Cancer
Mouse Model to Visualize Lgr5+ CSCs
(A) Schematic overview of the inducible fluores-
cent CRC mouse model generated to visualize
Lgr5+ CSCs.
(B) Diphtheria toxin (DT) treatment of CRC
Lgr5eGFP organoids. Representative confocal im-
ages of the effect of vehicle or DT on organoid
growth. Scale bar, 100 mm.
(C) Prolonged diphtheria toxin (DT) treatment of
mice orthotopically transplanted with CRC
Lgr5eGFP organoids. Average tumor growth upon
vehicle or DT treatment (n = 5). *p < 0.05 and
**p < 0.001. Data are presented as mean ± SEM; p
values were calculated using the Mann-Whitney
U test.
(D) Representative examples of primary tumors
and livers of mice subjected to either vehicle or DT
treatment for 8 weeks. Dashed lines highlight pri-
mary tumor edges, arrowheads indicate macro-
scopic metastatic lesions.
(E) Clonogenicity assay of sorted Lgr5+ CSCs
and Lgr5 cancer cells derived from CRC or-
ganoid cultures and orthotopic colorectal pri-
mary tumors. Data were collected 6 days after
plating (n = 3 independent experiments). Values
are presented as mean ± SEM; p values calcu-
lated using the unpaired t test with Welch’s
correction.
(F) Heatmap of differentially expressed transcripts
in cancer cells derived from two independent
biological replicates of organoids and orthotopic
primary tumors. Genesmarked in green are known
to be upregulated in intestinal stem cells; genes
marked in red are known intestinal differentiated
cell markers.RESULTS
Lgr5eGFP Labels Functional Stem Cells in Colorectal
Tumors
CRC models provide a unique opportunity to clarify the role of
CSCs and non-CSCs in the metastatic process, because hierar-
chical organization ismaintained during disease progression and
functional CSCs are marked by Lgr5 expression (Cortina et al.,
2017; de Sousa eMelo et al., 2017; Schepers et al., 2012; Shimo-
kawa et al., 2017). To study the role of CSCs in metastasis, we
combined the VillinCre-ERT2; APCfl/fl; KRASLSLG12D; TP53KO/KO
colorectal tumor mouse model with Lgr5DTR/eGFP (de Sousa e
Melo et al., 2017) and Confetti (Snippert et al., 2010) fluorescent
mouse models (Figure 1A). Upon injection of tamoxifen, the
entire intestinal tract of these mice becomes tumorigenic, and
these animals reach the humane endpoint before metastases
are formed. Just before the humane endpoint, we isolated the
tumorigenic colons of these mice and established primary
CRC organoids that consist of cancer cells expressing RFP-
Confetti and of CSCs that additionally express Lgr5-driven
eGFP and diphtheria toxin receptor (DTR) (referred as CRC
Lgr5eGFP organoids; Figures S1A and S1B). As previously
described, orthotopic transplantation of thesemurine CRC orga-
noids led to the formation of a single colorectal primary tumor570 Cell Stem Cell 26, 569–578, April 2, 2020that spontaneously metastasizes to liver and lungs (Figures
S1C–S1E) (Fumagalli et al., 2017, 2018; Roper et al., 2017; Taur-
iello et al., 2018). In line with previous findings (Cortina et al.,
2017; de Sousa e Melo et al., 2017; Shimokawa et al., 2017),
we found that Lgr5 is a good marker of the functional SCs both
in organoids and tumors, because selective ablation of the
Lgr5+ CSCs by diphtheria toxin (DT) (Figures S1F–S1I) caused
organoids to collapse and prevented tumor growth and metas-
tasis (Figures 1B–1D). Next, we developed a flow cytometry
strategy to isolate Lgr5+ CSCs and Lgr5 cancer cells from
both organoids and primary tumors (Figures S1J–S1M). Analysis
of DT-treated CRC Lgr5eGFP organoids, in which Lgr5+ CSCs are
selectively depleted, and post-sort confocal microscopy on
untreated CRC Lgr5eGFP organoids confirmed that our gating
strategy allowed to reliably isolate Lgr5+ and Lgr5 cancer cells
(Figures S1N and S1O). Clonogenic assays confirmed isolation
of functional Lgr5+ CSCs, as these cells were twice as clono-
genic as Lgr5 cancer cells (Figure 1E). Moreover, isolated
Lgr5+ CSCs showed higher expression of known intestinal SC
markers and lower expression of differentiated markers than
the Lgr5 cancer cells (Figure 1F) (de Sousa e Melo et al.,
2017; Shimokawa et al., 2017). Of note, we found a very signifi-
cant overlap in significantly differentially expressed genes
between Lgr5+ and Lgr5 cells from organoids and orthotopic
Figure 2. The Majority of Cells Escaping the Primary Colorectal Tumors Are Lgr5–
(A) Representative time-lapse intravital images of a non-migratory field within a CRC primary tumor. Note that the resolution of in vivo images is lower than of
ex vivo images because of great depth of imaging in living animals. Scale bar, 50 mm.
(B) Time-lapse intravital images of a migratory field showing primary tumor cell migration of Lgr5 and cancer cells (ROI, region of interest 1) and Lgr5+ CSCs
(ROI2). Dashed lines highlight the migratory cells, continuous lines mark the migratory tracks overtime. Scale bars, 50 mm. See also Videos S1 and S2.
(C) Representative time-lapse intravital images of Lgr5+ CSCs (upper panel) and Lgr5 cancer cells (lower panel) moving as cell clusters (see also
Videos S3 and S4). Scale bars, 50 mm.
(D) Display of the migratory tracks of Lgr5+ CSCs and Lgr5 cancer cells observed in (A) (left) and in (B) (right).
(E) Distribution of total displacement of Lgr5+ (green) and Lgr5 (red) migratory cells over a period of 4 h.
(legend continued on next page)
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primary tumors (hypergeometric test p value < 10100), indicating
that Lgr5+ and Lgr5 cancer cells maintain their specific cellular
identity when analyzed either in vitro or in vivo.
TheMajority ofMigratory TumorCells Are Lgr5 Negative
Using the developed orthotopic transplantation mouse model,
we addressed whether Lgr5+ CSCs and Lgr5 cancer cells
have differential metastatic behavior. In order to metastasize,
cancer cells first need to acquire traits that enable them to
leave the primary tumor (Hanahan and Weinberg, 2011). To
test which cancer cells escape from the primary site, we
filmed the behavior of Lgr5+ CSCs and Lgr5 cancer cells
in vivo using multiphoton microscopy (Figure 2; Videos S1,
S2, S3, and S4). Consistent with other tumor models (Beerling
et al., 2016; Hirata et al., 2015; Patsialou et al., 2013), in some
tumor lobes no migration was observed, whereas in other
lobes individual and clusters of Lgr5+ CSCs and Lgr5 cancer
cells invaded into the non-labeled stroma (n = 9 mice, 73
movies, 1,064 migratory events; Figures 2A–2C; Figure S2A;
Videos S1, S2, S3, and S4). Analysis of the migratory cells
(i.e., cells that displaced more than half a cell diameter in 4
h; Figures 2D and 2E) revealed that Lgr5+ CSCs and Lgr5
cancer cells mainly escaped as single cells and less frequently
as cell clusters (Figure 2F). Moreover, Lgr5 cancer cells might
have a slightly higher displacement and velocity than Lgr5+
CSCs (Figures 2G and 2H; Figures S2B and S2C). Surprisingly,
of the 1,064 migratory cells that escaped from the primary tu-
mors, the majority were Lgr5 (Figures 2E and 2I; 90.3% ±
2.8%, p < 0.0001), suggesting that most of the escaping cells
are in a more differentiated state.
The Vast Majority of Disseminating Cells in the
Circulation Are Lgr5 Negative
To determine whether both Lgr5+ CSCs and Lgr5 cancer
cells were able to enter the blood circulation, we drew blood
from the portal vein of mice bearing metastatic CRC to analyze
CTCs directly draining from the primary tumor using flow cy-
tometry (Figure 3A; Figure S3A). In all animals (n = 4) we de-
tected only Lgr5 circulating cancer cells (Figure 3B; Fig-
ure S3B). We extended the analysis by collecting systemic
oxygen-poor blood from the right ventricle of the heart of a
second batch of metastatic CRC mice to analyze CTCs com-
ing from metastases and observed that also in this case the
vast majority of circulating cancer cells were Lgr5 (98.4% ±
0.6%, n = 5; Figures S3C–S3E). Importantly, single-cell
mRNA sequencing validated that the CTCs displayed an
expression profile closely related to Lgr5 cancer cells and
did not show enriched expression of other CSC marker genes,
such as Prom1 (i.e., CD133), CD44, Aldh1a, and Bmi1 (Fig-
ure 3C; Figures S3F and S3G). Combined these data suggest
that the disseminating population of cancer cells is dominated
by Lgr5 cancer cells. Indeed, when we analyzed the livers of(F) Characterization of Lgr5+ CSCs and Lgr5 cancer cells migratory mode (i.e., ce
Data are presented as mean ± SEM (n = 9); p values were calculated using the u
(G and H) In vivo displacement (G) and velocity (H) of escaping Lgr5+ CSCs and L
indicate median ± interquartile range; p values were calculated using the Mann-W
(I) Fraction of escaping Lgr5+ CSCs and Lgr5 cancer cells observed in vivo in indiv
indicates the average value per animal. ****p < 0.0001. Red lines indicate mean ±
572 Cell Stem Cell 26, 569–578, April 2, 2020these mice, all single-cell metastases were Lgr5 (n = 6 mice;
Figures 3D and 3E; Figure S3H).
Stem Cell Plasticity Is Required for Metastatic Seeding
in the Liver
To understand whether escaping Lgr5 cancer cells could
initiate metastatic lesions, we analyzed larger metastases in
the livers. Although all single-cell and the majority of smaller
metastases were devoid of Lgr5+ CSCs, all larger metastases
(lesions larger than 80 mm in diameter) contained a population
of Lgr5+ CSCs (Figures 3D and 3E; Figure S3H). To test
whether Lgr5 cancer cells could give rise to full-blown meta-
static lesions, we monitored the real-time outgrowth of Lgr5
cancer cells seeding in the liver, by tracking the same meta-
static lesions with repeated multi-day intravital imaging
through an abdominal imaging window (Figure 3F). In all small
lesions initially containing only Lgr5 cancer cells, we
observed that some of the Lgr5 tumor cells underwent plas-
ticity and acquired Lgr5eGFP expression over time (Figure 3F).
Next, we neutralized this plasticity by ablating newly formed
Lgr5+ CSCs in early metastatic lesions and observed by intra-
vital imaging that metastasis composed by only Lgr5 cancer
cells stopped growing over time and ultimately regressed (Fig-
ures 3G and 3H; Figure S3I). Indeed, after 4 weeks of DT treat-
ment, no metastases could be observed (Figures 3I and 3J).
Combined this shows that the appearance of Lgr5+ CSCs is
indispensable for the outgrowth of metastases founded by
Lgr5 cancer cells.
To compare the efficiency of Lgr5 cancer cells and Lgr5+
CSCs to initiate metastases, we injected equal amounts of
sorted Lgr5+ CSCs and Lgr5 cancer cells into the mesenteric
vein, which are transported through the portal vein to the
liver. Four weeks later we found that, in addition to Lgr5+
CSCs, Lgr5 cancer cells were able to form metastases that
displayed similar morphology, though with slightly lower effi-
ciency (Figures 3K–3O; Figures S3J and S3K; n = 4 mice). Given
that most disseminating cells were Lgr5 and had the ability to
initiate metastatic growth, our data reveal that the majority of
metastases are seeded by Lgr5 cancer cells.
Lgr5– Clones Have the Intrinsic Capacity to Restore the
Cellular Hierarchy
Because growth of metastases seeded by Lgr5 cancer cells
requires cells to become Lgr5+, we next addressed what is
driving this plasticity. It has been suggested that cancer cells
can acquire SC properties when they are surrounded by a SC
niche, such as fibroblasts and immune cells, that provides
stemness-inducing signals (Sato and Clevers, 2013). To test
whether SC-inducing microenvironmental factors are deter-
ministic for cancer cell plasticity, we set up an organoid-form-
ing assay. In these pure epithelial culture systems, the three-
dimensional (3D) microenvironment was mimicked bylls escaping as single cells or as cell clusters (i.e., maintaining cell-cell contact).
npaired t test with Welch’s correction.
gr5 cancer cells. Each data point represents a cell. ****p < 0.0001. Red lines
hitney U test.
idual mice. Different shapes represent different animals (n = 9). Each data point
SEM; p value was calculated using the unpaired t test.
(legend on next page)
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Basement Membrane Extract (BME) and medium providing all
the essential SC-inducing factors present in the intestinal SC
niche, such as Wnt, R-spondin, and EGF (Sato and Clevers,
2013). By simply removing one or more of these niche factors,
it is possible to test whether intestinal epithelial cells and their
dynamics are dependent on essential microenvironmental sig-
nals (Drost et al., 2015; Fujii et al., 2016). We isolated single
Lgr5 circulating cancer cells from the blood and tested
whether they could be cultured in medium without any SC-
inducing factors. Interestingly, in this minimal medium we
were able to grow organoids from Lgr5 circulating cancer
cells, and also here we observed the appearance of Lgr5+
CSCs over time (Figures 4A and 4B). Moreover, these Lgr5+
cancer cells were functional SCs, as selective ablation of
these cells by acute or chronic DT treatment in both orga-
noid-derived and primary tumor-derived cells abolished orga-
noid outgrowth (Figures 4C; Figures S4A–S4F). To exclude
that residual growth factors in the BME matrix could trigger
cancer cell plasticity in our culture system, we confirmed
these data in an engineered 3D matrix consisting of growth
factor-free synthetic hydrogel (Figures 4D and 4E). Finally, to
test whether plasticity can be enhanced by microenviron-
mental factors that are released by cancer associated fibro-
blasts, we cultured Lgr5 cells in minimal medium supple-
mented with HGF, FGF, IL4, and IL13 (Chen et al., 2018;
Knuchel et al., 2015; Lenos et al., 2018; Todaro et al., 2007,
2014). Indeed, we observed enhanced plasticity (i.e., appear-
ance of Lgr5+ cells) in medium supplemented with HGF and
FGF compared with a basal level of plasticity in minimal
CRC medium (Figure 4F). These data suggest that clones
seeded by Lgr5 cancer cells have the intrinsic capacity to
re-establish the cellular hierarchy, even in conditions devoid
of microenvironmental SC-inducing signals, and that this plas-
ticity can be further enhanced by microenvironmental factors
such as HGF and FGF.Figure 3. Lgr5– Cancer Cells Are the Disseminating Cells in CRC
(A) Experimental setup: mice bearing metastatic CRC were used to sample blo
circulating tumor cells.
(B) Cumulative FACS profile of circulating Lgr5+ CSCs and Lgr5 cancer cells (n =
blood sample in Figure S3B.
(C) Heatmap of differentially expressed genes in Lgr5+ and Lgr5 cancer cells isola
are known to be upregulated in intestinal stem cells; genes marked in red indica
(D) Representative confocal images of spontaneous liver metastases groupe
bar, 100 mm.
(E) Metastases are subdivided in lesions composed of only Lgr5 cancer cells (r
(the analysis includes 132 metastatic lesions, n = 6).
(F) Intravital multi-day imaging of liver metastases hatching from Lgr5 cancer ce
next to the corresponding panels. Scale bars, 50 mm.
(G) Representative images of a liver metastasis followed overtime by intravital im
diphtheria toxin (DT) administration. Dashed lines highlight metastasis border. Sc
(H) Size of DT-treated metastatic lesions followed by intravital imaging (n = 5), norm
(I) Representative histochemistry images of livers of mice subjected mesenteric ve
DT treatment for 4weeks. ROI, region of interest. Asterisks indicate metastatic foc
corresponding overview images. Scale bars, 500 mm.
(J) Representative examples of livers of mice of mice subjected mesenteric vein
4 weeks.
(K) Number of metastatic foci derived from mesenteric vein injection of Lgr5+ CS
(L) Metastatic load upon injection of Lgr5+ CSCs or Lgr5 cancer cells. Similar sh
interquartile range; p values were calculated using the paired t test (*p < 0.05).
(M–O) Representative examples of metastases generated from Lgr5+ CSCs (M) a
574 Cell Stem Cell 26, 569–578, April 2, 2020DISCUSSION
Although epithelial hierarchy is often seen as a static, one-
directional route from SCs to differentiated cells, our study
draws a more dynamic picture of CRC, particularly of the
metastatic setting. We showed that, in addition to CSCs,
non-CSCs are also capable of giving rise to colorectal liver
metastases. Although CSCs are present in the primary tumor
and in the migratory population (Figure 2), we did not detect
them in circulation. As already shown for healthy intestine
(Sato et al., 2011; Serra et al., 2019), CSCs may lose Lgr5
expression and stemness once they are not supported by
the surrounding SC niche and therefore may be forced into a
Lgr5 state. Regardless of the origin of the disseminating
non-CSCs, non-CSCs are in fact the major seeding cells, while
conversion to CSCs at the metastatic site is required for effi-
cient metastatic outgrowth. Therefore, cancer cell plasticity,
rather than seeding of CSCs, is a key step in the formation
of CRC metastases. To confirm the occurrence of plasticity
in human tissues, we orthotopically transplanted human tumor
organoids characterized by SC Ascl2 reporter that labels
Lgr5+ CSCs (i.e., STAR probe; see Oost et al., 2018) (Fig-
ure S4G). Similar to their murine counterpart, these experi-
ments showed that the major disseminating population
(CTCs) was Lgr5 (Figure S4H). Moreover, human Lgr5 cells
efficiently seed metastases that contained Lgr5+ CSCs (Fig-
ures S4I and S4J). Plasticity in human cancer cells can happen
independently of SC-inducing factors, as Lgr5+ CSCs ap-
peared in organoids that were seeded by Lgr5 cells and
cultured in minimal CRC medium (Figure S4K). These experi-
ments showed that differentiated cancer cells are able to
form metastases, are plastic, and can re-establish the cellular
hierarchy also in the human setting (Figures S4H–S4K).
Cellular plasticity of epithelial cells has already been reported
in healthy intestine (Ritsma et al., 2014; Tetteh et al., 2016;od from the portal vein. Blood was analyzed using FACS for the presence of
4). The color coding links individual circulating tumor cells to the corresponding
ted fromprimary tumors, CTCs, and livermetastasis. Genesmarkedwith green
te known intestinal differentiated cell markers.
d per diameter range. Dashed lines highlight the metastasis edges. Scale
ed) or lesions containing Lgr5+ CSCs (green) and grouped per diameter range
lls. Dashed lines highlight metastasis edges. Yellow boxed areas are enlarged
aging demonstrating growth and regression upon depletion of Lgr5+ CSCs via
ale bar, 100 mm.
alized to the first time point. The red line represents the example shown in (G).
in injection of FACS-sorted Lgr5 cancer cells and treated with either vehicle or
i; dashed lines highlight metastasis edges. Boxed areas are enlarged next to the
injection of CRC Lgr5eGFP and treated with either vehicle or DT treatment for
Cs or Lgr5 cancer cells.
apes represent paired experiments (n = 4). Data are presented as median with
nd Lgr5 cancer cells (N), boxed area enlarged in (O). Scale bars, 100 mm.
Figure 4. Disseminating Lgr5– Cancer Cells Undergo Niche-Independent Cellular Plasticity
(A) Representative example of organoid formation assay of sorted Lgr5 circulating cancer cells. Dashed lines highlight organoids edges. Arrowhead indicates
the appearance of a Lgr5+ CSC. Scale bar, 20 mm.
(B) Quantification of cancer cell plasticity (i.e., emergence of Lgr5+ CSCs) in the organoid-forming assay of sorted Lgr5 circulating cancer cells grown in minimal
CRC medium. Data are presented as mean ± SEM (n = 3 independent experiments).
(C) Clonogenicity assay in minimal CRCmedium of sorted Lgr5+ CSCs and Lgr5 cancer cells derived fromCRC organoid cultures. Single cells were subjected to
either vehicle or diphtheria toxin (DT) treatment (n = 3 independent experiments). Data were collected 6 days after plating. Values are presented as mean ± SEM;
***p < 0.0001, calculated using the unpaired t test with Welch’s correction.
(D) Representative example of organoid formation assay of sorted Lgr5 cancer cells cultured in synthetic hydrogel. Dashed lines highlight organoids edges.
Scale bar, 50 mm.
(E) Representative images of the effect of vehicle or diphtheria toxin (DT) on sorted Lgr5+ CSCs and Lgr5 cancer cells cultured in synthetic hydrogel 6 days after
plating (n = 3 independent experiments). Scale bar, 200 mm.
(F) Quantification of cancer cell plasticity (i.e., emergence of Lgr5+ CSCs) of sorted Lgr5 cancer cells grown in either minimal CRC medium (control) or medium
containing FGF-2 (10 ng/mL), HGF (75 ng/mL), IL4 (20 ng/mL), IL13 (100 ng/mL), and IL4 and IL13. n = 3 independent experiments. *p < 0.05 and **p < 0.001,
calculated using the unpaired t test. Data are represented as mean ± SEM.Tian et al., 2011; van Es et al., 2012) and as recently reviewed
by de Sousa e Melo and de Sauvage (2019). Upon targeted
depletion of the healthy Lgr5+ SC population, more specialized
Lgr5 cells enter the SC niche and are instructed to revert to
Lgr5+ SCs, thereby restoring tissue homeostasis (Ritsma
et al., 2014; Tetteh et al., 2016; Tian et al., 2011; van Es
et al., 2012). The intestinal SC niche consists of supporting
cells producing stemness-inducing factors, such as Wnt, R-
spondin, and EGF. Similar plasticity processes have been
observed in primary CRC tumors, and various microenviron-
mental signals have been highlighted as responsible for the
switch of non-CSCs to CSCs (Lenos et al., 2018; Schwitalla
et al., 2013; Vermeulen et al., 2010). However, our data also
suggest that cancer cell plasticity can be triggered indepen-
dently of stemness-inducing factors provided by SC niches.
Nevertheless, we also show that factors released by fibro-
blasts, such as FGF and HGF, can enhance plasticity. Regard-
less of this enhancement, our data suggest that specifically
targeting CSCs and/or the SC-inducing niche, as previously
proposed (de Sousa e Melo and de Sauvage, 2019), may notbe enough to completely prevent metastatic disease, which
is the leading cause of cancer-related death. Instead, endog-
enous cellular plasticity should be co-targeted to inactivate
any potential seeds of metastasis, and future studies should
aim to uncover microenvironment-independent mechanisms
leading to cell plasticity.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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B Immunohistochemistry and fluorescent imaging
B In vivo time-lapse imaging of primary tumors
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B Intrahepatic injection
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B Comparison of Lgr5+ and Lgr5- metastatic efficiency
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26Sortm1(CAG-Brainbow2.1)Cle/J
The Jackson Laboratory Cat# 013731
Mus musculus_Lgr5DTR-eGFP Genentech (Tian et al., 2011) N/A
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FlowJo 10.6.1 BD Biosciences https://www.flowjo.com/
GraphPad Prism GraphPad Software https://www.graphpad.com/scientific-
software/prism/
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Jvr Jittering Corrector N/A
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation of a colorectal cancer genetic mouse model
The VillinCre-ERT2 mouse model (The Jackson Laboratory, cat. no. 20282) was combined with the APCfl/fl, KRASLSL-G12D/+,
TP53KO/KO mouse model in order to generate a VillinCre-ERT2; APCfl/fl; KRASLSL-G12D/+; TP53KO/KO, a Tamoxifen-inducible triple
mutant genetic mousemodel. The color randomizer R26R-Confetti (gifted by the Clevers laboratory, Hubrecht Institute, NL (Snippert
et al., 2010) allele and stem cell fluorescent reporter Lgr5DTR-eGFP (gifted by De Sauvage laboratory, Genentech, USA (Tian et al.,
2011)) were bred in to finally generate the VillinCre-ERT2; APCfl/fl; KRASLSL-G12D/+; TP53KO/KO; R26R-Confetti; Lgr5DTR-eGFP genetic
mousemodel in amixed background. In thesemice Lgr5+ cells (e.g., the stem cells in the intestine) are labeledwithmembrane-bound
eGFP. Activation of the inducible Cre upon administration of Tamoxifen initiates formation of tumors which are restricted to the in-
testine and promotes the expression of one of the four Confetti colors, thereby specifically color-coding the tumor cells. Since tumors
develop throughout the whole intestinal tract, these mice reach the humane endpoint 5 to 6 days after high dose (200mg/kg)
Tamoxifen (Merk cat. no. T5648) injection.
Isolation and culturing of mouse organoids
8 weeks old VillinCre-ERT2; APCfl/fl; KRASLSL-G12D/+; TP53KO/KO; R26R-Confetti; Lgr5DTR-eGFP transgenic mice were injected with
200mg/kg Tamoxifen and sacrificed 4 days after induction. Colorectal cancer organoids were isolated from two independent
VillinCre-ERT2; APCfl/fl; KRASLSL-G12D/+; TP53KO/KO; R26R-Confetti; Lgr5DTR-eGFP transgenic mice as previously described(Sato
et al., 2009). Minimal colorectal cancer organoid culture medium (minimal CRC medium) contained advanced DMEM/F12 medium
(adDMEM/F12; Thermo Fisher Scientific, cat. no. 12634-010), B27 2% (Thermo Fisher Scientific, cat. no. 17504-044), N-acetylcys-
teine 1.25 mM (Merk, cat. no. A9165) and Noggin 1% (PeproTech, cat. no. 120-10C). In order to discriminate between CSCs
(Lgr5DTR-eGFP) and Lgr5- tumor cells, RFP-Confetti labeled cells were isolated by flow cytometry and expanded in culture as tumor
organoid lines.
Acceptor mice for transplantation experiments
8 – 14 weeks old male and/or females NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG, The Jackson Laboratory cat. no. 005557) mice were
used as acceptors for subcutaneous injection, orthotopic transplantation and mesenteric vein injection. All experiments were per-
formed in accordance with the Animal Welfare Committees of the Royal Netherlands Academy of Arts and Sciences and the
Netherlands Cancer Institute, the Netherlands. Animals were kept at the Hubrecht animal facility in Utrecht or at the Netherlands Can-
cer Institute facility in Amsterdam, the Netherlands. For every experimental condition, at least 4 mice were used. No animals were
excluded from analyses.When experiments consisted ofmultiple conditions, eithermales or females of the same litter were randomly
assigned to each group.e2 Cell Stem Cell 26, 569–578.e1–e7, April 2, 2020
Human organoids
The experiments were performed with patient-derived P19bT human organoids (van de Wetering et al., 2015), mutated in TP53,
PIK3CA, BRAF, ERBB3, RNF43) constitutively labeled with H2B-mNeonGreen while cancer stem cells specifically express
singleTomato-NLS driven by a ASCL2-responsive minigene (STAR, (Oost et al., 2018)).
METHOD DETAILS
Orthotopic transplantation of murine organoids
Orthotopic transplantation of colorectal cancer organoids was performed as previously described (Fumagalli et al., 2017, 2018). In
brief, the day before transplantation organoids were collected and dissociated into small cell clumps. About 250,000 cells were
plated in 15 ml drops neutralized Rat Tail High Concentrated Type I Collagen (Corning, cat. no. 354249) and let to recover overnight
at 37C, 5%CO2 in CRCmedium containing 100 mMY-27632 (Abmole, cat. no. M1817). At the day of transplantation, acceptor mice
were sedated using isoflurane inhalation anesthesia (~2% isoflurane/O2 mixture). Before surgery, the mice were treated subcutane-
ously with a single dose of buprenorphine (Buprecare, Multidosis-Astfarma, 3mg per mouse). The cecum was exposed through a
midline abdominal incision and a collagen drop containing tumor cells was surgically transplanted in the caecal submucosa. The tu-
mor growth was monitored weekly by abdominal palpation.
Orthotopic transplantation of human organoids
Transplantations were performed as described above using 1.5 105 human organoid-derived cells embedded in Rat Tail High
Concentrated Type I Collagen (Corning, cat. no. 354249).
Flow cytometry on organoids
Colorectal cancer organoids were collected and mechanically dissociated with a fire-pointed glass pipet. Subsequently cells were
incubated in in TryplE (Thermo Fisher Scientific, cat. no. 12605-010) mix containing 100 mM Y-27632 (Abmole Bioscience, cat. no.
M1817), 4mg/ml DNase I (Sigma-Aldrich, cat. no. 10104159001) for 10 minutes at 37C and spun down. Cells were resuspended
in FACS buffer containing 2% B27 (Thermo Fisher Scientific, cat. no. 17504-044), 1.25 mM N-acetylcysteine (Sigma-Aldrich, cat.
no. A9165), 1% Noggin (PeproTech, cat. no. 120-10C), 100 mM Y-27632 (Abmole Bioscience, cat. no. M1817), 4mg/ml DNase I
(Merk, cat. no.4716728001), 0.01%FCS (Merk, cat. no. F7524) in PBS and filtered through a 100 mmand 35 mmstrainers (BD Falcon).
DAPI 1ng/ml (Thermo Fisher Scientific, cat. no. D1306) was added right before sorting. Cells were sorted on a FACS AriaII Special
Ordered Research Product or a FACS Aria Fusion (BD Biosciences). The sort strategy is illustrated in Figures S1J–S1N. A broad
FSC/SSC gate was followed by gates excluding doublets and selection of DAPI--living cells. RFP-Confetti+ tumor cells were subdi-
vided in (Lgr5)eGFP+ and (Lgr5)eGFP- using stringent gating. For each experiment, the quality of the sorting was assessed by exam-
ination of the sorted cells at a confocal microscope (as in Figure S1O).
Flow cytometry on primary mouse material
Orthotopic colorectal cancer tumors were collected and minced on ice using sterile scalpels. The tumor mass was digested at 37C
for about 1 hour in 5mg/ml Collagenase II brown powder (Thermo Fisher Scientific, cat. no. 17101015) dissolved in advanced DMEM/
F12 medium (adDMEM/F12; Thermo Fisher Scientific, cat. no. 12634-010) containing 100 mM Y-27632 (Abmole Bioscience, cat. no.
M1817), 4mg/ml DNase I (Merk, cat. no. 4716728001), 20 mg/ml Hyaluronidase (Merk, cat. no. HX0514-1). Digested cell clumps were
incubated in TryplE (Thermo Fisher Scientific, cat. no. 12605-010) mix containing 100 mM Y-27632 (Abmole Bioscience, cat. no.
M1817), 4mg/ml DNase I (Merk, cat. no. 4716728001) for 15 minutes at 37C and spun down. The cell pellet was resuspended in
FACS buffer (composition described above) and filtered through a 35 mmstrainer (BD Falcon). DAPI 1ng/ml (Thermo Fisher Scientific,
cat. no. D1306) was added right before sorting.
Blood was collected from mice bearing metastatic CRC either via portal vein puncture or right-ventricle cardiac puncture,
7-10 weeks after orthotopic colorectal cancer organoids transplantation. The red blood cells were depleted by NH4Cl treatment.
The remaining circulating tumor cells and immune cells were spun down (4 minutes 500 RCF at RT). Tumor cells and blood cells
were blocked in 80%FACSbuffer / normal goat serum (Monosan,monx10961) for 10minutes on ice before labelingwith the following
antibodies: biotin-conjugated anti-mouseCD41 clone eBioMWReg30 (Thermo Fisher Scientific, cat. no. 13-0411-82) and anti-mouse
CD45 clone 30-F11 (Thermo Fisher Scientific, cat. no. 13-0451-85). Secondary labeling was performed using streptavidin-conju-
gated AF647 (Thermo Fisher Scientific. no. S-32357). Cells were filtered through a 35 mm strainer (BD Falcon). DAPI 1ng/ml (Thermo
Fisher Scientific, cat. no. D1306) was added right before sorting.
Cells were sorted on a FACS AriaII Special Ordered Research Product or a FACS Aria Fusion (BD Biosciences). The sort strategy is
illustrated in Figures S1J and S1L and Figures S3A and S3D. A broad FSC/SSC gate was followed by gates excluding doublets and
selection of DAPI--living cells. Afterward, immune cells andmegakaryocytes were excluded in a dump channel. RFP-Confetti+ tumor
cells were subdivided in Lgr5-eGFP+ and Lgr5-eGFP- using stringent gating. The quality of the sorting was assessed afterward by
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Flow cytometry on human xenografts
Blood was collected from mice bearing human metastatic CRC either via right-ventricle cardiac puncture, 7-10 weeks after ortho-
topic colorectal cancer organoids transplantation. Samples were prepared and analyzed at the FACS as described above for exper-
iments with the murine CRC model.
H2B-mNeonGreen+ tumor cells were subdivided in STAR-NLS-singleTomato+ and STAR-NLS-singleTomato- using stringent
gating. The quality of the sorting was assessed by post-sort purity check and examination of the cells at a confocal microscope.
Immunohistochemistry and fluorescent imaging
Tissues were fixed periodate-lysine-4% paraformaldehyde (PLP)(McLean and Nakane, 1974) buffer overnight at 4C, incubated in
30% sucrose overnight at 4C and embedded in Tissue-Tek (Sakura, cat. no. 4583). Organs were cryosectioned and staining
were performed on 20-30 mm sections. The stainings were performed with the following primary antibodies: anti-b-catenin clone
14 (BDBioscience, cat. no. 610154), anti-GFP (Abcam, cat. no. ab6673), anti-RFP (Rockland, cat. no. 600-401-379). Stained sections
were imaged with inverted Leica TCS SP5 and TCS SP8 confocal microscopes (Mannheim, Germany). All images were collected in
12 bit with 25Xwater immersion (HC FLUOTAR L N.A. 0.95WVISIR 0.17 FWD 2.4mm) or 20X dry (HCX IRAPON.A. 0.70WD 0.5mm)
objectives.
In vivo time-lapse imaging of primary tumors
About 250,000 VillinCre-ERT2; APCfl/fl; KRASLSL-G12D/+; TP53KO/KO; RFP-Confetti; Lgr5DTR-eGFP organoid-derived cells were mixed in
100 ml Matrigel (Corning, cat. no. 356231) and injected subcutaneously into the flank of recipient NSG mice. Experiments were per-
formed on 9 NSGmice with organoid lines isolated from two independent VillinCre-ERT2; APCfl/fl; KRASLSL-G12D/+; TP53KO/KO; R26R-
Confetti; Lgr5DTR-eGFP transgenic mice. Specifically, 4 NSGwere injected with the organoid line derived from the first GEMMdonor, 5
NSG with organoid line derived from the second GEMM donor. Time-laps intravital imaging was performed on tumors of about
125 mm3. During the entire procedure mice were sedated using isoflurane inhalation anesthesia (1.5% isoflurane/ O2 mixture).
The tumor was surgically exposed, and the mouse was placed in a custom designed imaging box with its head in a facemask
constantly delivering anesthesia. The imaging box and the microscope were adjusted at 36.5C using a climate chamber. Intravital
images were acquired with an inverted Leica TCS SP5 or TCS SP8 AOBS two-photon microscope (Mannheim, Germany) with a
chameleon Ti:Sapphire pumped Optical Parametric Oscillator (Coherent Inc. Santa Clare, CA, USA). The microscopes are equipped
with 2 non-descanned and 2 hybrid detectors: GFP and RFP were simultaneously excited at 940 nm and detected with hybrid de-
tectors. Second harmonic generation (Collagen I stroma) was detected with a non-descanned detector. Images were collected every
hour for a period of 4 to 8 hours during which the mouse was kept sedated and alive, constantly hydrated with subcutaneous infusion
of glucose and electrolytes (NutriFlex special 70/240, Braun, 100 ml/h). All images were collected in 12 bit and acquired with a 25X
water immersion (HC FLUOTAR L N.A. 0.95 W VISIR 0.17 FWD 2.4 mm) objective.
Multi-day imaging of liver metastasis
Lgr5- cancer cells were seeded into the liver parenchyma of acceptor mice either bymesenteric vein injection (of about 400,000 Lgr5-
sorted cells) or direct liver parenchyma injection (of about 60,000 Lgr5- sorted cells). For the diphtheria toxin experiment mice were
treated every other day with 50 mg/kg Diphtheria Toxin (Merk, cat. no. D0564) administered via intraperitoneal injection every other
day. 6-8 days after cells seeding, an abdominal imaging window was applied on the liver of the acceptor mice (Ritsma et al., 2013).
Before surgery the mice were treated with a sub-cutaneous injection of buprenorphine (Buprecare, Multidosis-Astfarma, 3mg per
mouse). The surgery was performed under aseptic conditions. Animals were sedated with ~2% isoflurane/compressed air mixture.
After surgery, the mice were kept at 37C until fully recovered. For every imaging session, mice were sedated using isoflurane inha-
lation anesthesia (~1.0% isoflurane/ compressed air mixture). The mice were placed in a custom designed imaging box while kept
under constant anesthesia. The imaging box and the microscope were adjusted at 36.5C using a climate chamber. Between the
imaging sessions, mice were let recover in their cage. Intravital images were acquired with an inverted Leica SP8 Dive system (Man-
nheim, Germany) with a MaiTai eHP DeepSee laser (Spectra-Physics). The imaging areas were retraced in subsequent imaging ses-
sions by storing the stage coordinates, and by visual landmarks such as blood vessels as described in43. Themicroscope is equipped
with a 4Tune non-descanned detector configured with 4 hybrid detectors: Lgr5-DTReGFP, Confetti-RFP were simultaneously excited
at 940 nm and detected with non-descanned hybrid detectors, together with second harmonic generation (Collagen I, stroma). All
images were collected in 12 bit and acquired with a 25x water immersion objective with a free working distance of 2.40 mm
(HC FLUOTAR L 25x/0.95 W VISIR 0.17).
Mesenteric vein injection
FACS-sorted cells were resuspended in 100 ml of sterile PBS and injected in the mesenteric vein of acceptor mice as previously de-
scribed(van der Bij et al., 2010). Mice were sedated isoflurane inhalation anesthesia (~2% isoflurane/ O2mixture). Before surgery, the
mice were treated with a sub-cutaneous dose of buprenorphine (Buprecare, Multidosis-Astfarma, 3mg permouse). After surgery, the
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Intrahepatic injection
FACS-sorted cells were resuspended in 100 ml of sterile Matrigel (Corning, cat no. 356231) and PBS mix (2.5:1) and injected the liver
parenchyma. The surgical procedure was performed under isoflurane inhalation anesthesia (~2% isoflurane/ O2mixture). Before sur-
gery, the mice were treated with a sub-cutaneous dose of buprenorphine (Buprecare, Multidosis-Astfarma, 3mg per mouse). After
surgery, the mice were kept at 37C until fully recovered.
Organoid formation assays
Lgr5+ cancer stem cells, Lgr5- cancer cells from either organoids or primary tumors and Lgr5- circulating tumor cells were isolated by
FACS according to their eGFP expression level as described before. Lgr5+ cancer stem cells, Lgr5- cancer cells from either organoids
or primary tumors were seeded in 20 ml BME (R&D systems, cat. no. 3533-005-02) drops containing 500 cells/drop while Lgr5- circu-
lating tumor cells were seeded in 20 ml BME drops containing 100 cells/drop. Cells were cultured in CRC medium (see above)
containing 100 mM Y-27632 (Abmole Bioscience, cat. no. M1817). Cells were imaged daily with an inverted Leica TCS SP5 confocal
microscopes (Mannheim, Germany). All images were collected in 12bit with a 25X water immersion (HC FLUOTAR L N.A. 0.95 W
VISIR 0.17 FWD 2.4 mm) or with a 20X dry (HCX IRAPO N.A. 0.70 WD 0.5 mm) objective. Enhancement of plasticity by microenvi-
ronmental factors was tested by collecting 10000 viable Lgr5- single cells via FACS and plating them in BME (R&D systems, cat.
no. 3533-005-02) over three wells with a density of 50-300 cells per well of a glass-bottom 384-well plate (Corning, cat. no. 4581).
Organoids were supplemented with either minimal culture medium (control), or medium including 75 ng/ml HGF (R&D
Systems, cat. No. 294-HG), 10ng/ml FGF-2 (Thermo Fisher Scientific, cat. no. PHG0021), 20ng/ml IL4 (Peprotech, cat. no.
214-14), 100 ng/mL IL13 (Peprotech, cat. no. 214-13). Organoids were imaged live using a Leica-based spinning disk confocal mi-
croscope equipped with an Andor Dragonfly system, using a water 25x objective (HC-Fluotar, N.A. 0.95) with the Argon-laser of
488nm and the Diode-laser of 561nm using a 40mm pinhole and Andor sCMOS Zyla 4 2p camera. while kept at 37C and and 5%
CO2 overflow. Organoids were scored at day 0 and after 5 (Figure 4F) or10 days (Figure S4K) of culture for expression of Lgr5eGFP.
In vitro Diphtheria Toxin treatment
Lgr5+ cancer stem cells, Lgr5- cancer cells from either organoids or primary tumorrs were seeded in BME as described above. Diph-
theria Toxin (100ng/ml, Merk, cat. no. D0564) or vehicle (demi-water) were added to the CRC culture medium (see above) containing
100 mM Y-27632 (Abmole Bioscience, cat. no. M1817). The medium was refreshed every other day.
In vivo Diphtheria Toxin treatment
50 mg/kg Diphtheria Toxin (Merk, cat. no. D0564) or vehicle (demi-water) were administered via intraperitoneal injection every
other day.
Hydrogel assay
Organoid-derived Lgr5+ and Lgr5- were sorted as described above, resuspended in 20% sucrose andmixed with Puramatrix Hydro-
gel (3mg/ml, Corning, cat. no. 354250), purified fibronectin (0.25mg/ml, Merck, cat. no. FC010), purified laminin-111 (50 mg/ml, Merk,
cat. no. L2020) The mixture was plated as a drop and gelation of the hydrogel was initiated by carefully adding advanced DMEM/F12
medium (adDMEM/F12; Thermo Fisher Scientific, cat. no. 12634-010). Hydrogels were allowed to form for 30 min at 37C after which
the medium was changed to full organoid growth medium with 100 mMY-27632 (Abmole Bioscience, cat. no. M1817). Organoid me-
dium was refreshed every two-three days.
Comparison of Lgr5+ and Lgr5- metastatic efficiency
Lgr5+ and Lgr5- cells were isolated from 4 different murine primary tumors with stringent gating (sorted strategy described above,
Figure S1J and Figure S3A) and post-sort purity was assessed by resorting a fraction of every sorted sample. Only samples above
98% purity used for further in vivo experiments. Cells were inoculated via mesenteric vein injection as described above. Every in vivo
biological replicate included: 1. a recipient mouse injected with 50,000 Lgr5- cells; 2. a recipient mouse injected with 50,000 Lgr5+
cells; 3. when the purity control is between 98%–100%, a recipient mouse injected with a purity control (Lgr5+ cells), established via
the percentage of cells falling out from the stringent Lgr5- gate during post-sort purity analysis (i.e., cells that might have mistakenly
been sorted as Lgr5-). Four weeks after injection the mice were sacrificed and the livers were inspected for presence of metastases
under a fluorescence-stereo microscope (Leica). Importantly, none of the mice injected with purity controls showed formation of me-
tastases. Tissues were fixed periodate-lysine-4% paraformaldehyde (PLP) buffer (McLean and Nakane, 1974) overnight at 4C, incu-
bated in 30% sucrose overnight at 4C and embedded in Tissue-Tek (Sakura, cat. no. 4583).
Comparison of STAR+ and STAR- metastatic efficiency
Experiments were performed as described above for murine cancer cells. Human STAR+ and STAR- cells were isolated by FACS and
post-sort purity was assessed by resorting a fraction of every sorted sample. 50,000 STAR+ or STAR- were injected in themesenteric
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the stringent STAR- gate during post-sort purity analysis was also included every time that the experiment was performed. Four
weeks after injection the mice were sacrificed and the livers were inspected for presence of metastases under a fluorescence-stereo
microscope (Leica). Importantly, none of the mice injected with purity controls showed formation of metastases. Tissues were fixed
periodate-lysine-4% paraformaldehyde (PLP) buffer (McLean and Nakane, 1974) overnight at 4C, incubated in 30% sucrose over-
night at 4C and embedded in Tissue-Tek (Sakura, cat. no. 4583).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics was performed using GraphPad Prism. Paired or unpaired t test (with Welsh correction) was used when data showed
normal distribution (verified with normality tests, provided by GraphPad Prism), whereas Mann-Whitney U test was used for data
that did not display normal distribution. Adoption of one statistical test or the other is indicated for each experiment in the figure
legend.
Flow cytometry
Data were manually analyzed using FlowJo 10.6.1 (https://www.flowjo.com/).
Fluorescent images (fixed samples)
Images were converted to RGB using Fiji (https://imagej.nih.gov/ij/) and only if necessary, corrected for bleed through, smoothened,
cropped, rotated and contrasted linearly. Images were quantified using Fiji.
Intravital imaging of primary tumors
Videos were corrected for XYZ drift using a custom-made software (written in Visual Studio 2010 in the .NET framework for Visual
Basics. Codes are available on request from J.v.R.) and if needed additionally with match motion compensation software program
to correct for rigid and elastic tissue deformation as extensively described byNoordmans and colleagues (Verdaasdonk, 2006). The Z
correction of each time point was done manually and the XY correction was done automatically as follows: all images over time were
corrected to the image of the first time point. The correction is based on finding the highest spatial correlation between the images.
The spatial correlation for pixels in which the gray value in both images are > 0 were analyzed with the Pearson’s correlation coef-
ficient. Then, the imaged that needs to be corrected wasmoved one pixel to the left, and the correlation was recalculated. If this led to
a higher correlation, all pixels in the imageweremoved one pixel to the left. The correlation was calculated for amove of the corrected
image to the left, right, up or down. This procedurewas repeated iteratively until the coefficient no long increased. After the full correc-
tion, the correctness of the XY correction was visually inspected and manually adjusted if required. To experimentally test the suc-
cess of the XYZ correction, the position of randomly picked cells were tracked, and if the movement is less than half a cell diameter in
4 hours, we called the correction successful (see examples in Figure 2D).
Images were further processed using Fiji. Frames were converted to RGB and only if necessary, corrected for bleed through with
AND/OR function, smoothened, cropped, rotated and contrasted linearly. Migration was quantified manually using Fiji. Statistical
analysis was performed in GraphPad Prism using non-parametric Mann-Whitney U test or unpaired t test with Welch’s correction.
Intravital imaging of liver metastasis
Images were processed and analyzed using Fiji. Frames were converted to RGB and only if necessary, corrected for bleed through
with AND/OR function, smoothened, cropped, rotated and contrasted linearly.
Organoid formation assays
Organoids were counted manually by scoring them using a stereomicroscope. Fluorescent images were processed using Fiji.
Frames were converted to RGB and only if necessary, corrected for bleed through with AND/OR function, smoothened, cropped,
rotated and contrasted linearly. Lgr5-eGFP expression was scored manually.
Metastasis scoring
Whole livers were sectioned in 50 mm thick slices andmetastasis imagedwith an inverted Leica TCSSP5 or a Leica TCSSP8 confocal
microscope (Mannheim, Germany). All images were collected in 12 bit with 25X water immersion (HC FLUOTAR L N.A. 0.95 W VISIR
0.17 FWD 2.4 mm). Images were converted to RGB using Fiji and only if necessary, corrected for bleed through, smoothened, crop-
ped, rotated and contrasted linearly. Images were quantified using Fiji. Quantification was blinded concerning to the data group allo-
cation. Statistical analysis was performed with GraphPad Prism.
Single-cell mRNA sequencing
Single-cell mRNA sequencing was performed using Sort-seq as described in Muraro et al. (Muraro et al., 2016). Single-cell libraries
were sequenced on Illumina NextSeq500 with 75bp paired end reads. Read1 contains the cell barcode and Unique Molecule
Identifier, read2 was mapped to the mm10 RefSeq transcriptome using Burrows-Wheeler Aligner with standard parameters. Seurate6 Cell Stem Cell 26, 569–578.e1–e7, April 2, 2020
(R package Seurat (Stuart et al., 2019)) was used for analyzing the single cell data. Single cell transcriptomes were filtered for cells
that had at least 1,000 unique transcripts and subsequently log-normalized to 10,000 transcripts per cell. Clustering was performed
on the first 13 principal components and clusters were identified with a resolution of 1. Differential gene expression analysis was per-
formed with the roc test. Cell type identification was performed based on the differentially expressed genes between the clusters.
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